Research And Markets Research And Markets
0 CHECKOUT

Neuroendocrine Tumors Drug Pipeline Update

  • ID: 1196710
  • August 2016
  • Region: Global
  • Bioseeker
1 of 2

There are today 121 companies plus partners developing 138 neuroendocrine tumor drugs in 199 developmental projects in cancer. In addition, there is 1 suspended drug and the accumulated number of ceased drugs over the last years amount to another 24 drugs. Neuroendocrine Tumors Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 122 different targets. All included targets have been cross-referenced for the presence of mutations associated with human cancer. To date 117 out of the 118 studied drug targets so far have been recorded with somatic mutations. The software application lets you narrow in on these mutations and links out to the mutational analysis for each of the drug targets for detailed information. All drugs targets are further categorized on in the software application by 38 classifications of molecular function and with pathway referrals to BioCarta, KEGG, NCI-Nature and NetPath.

Drug Pipeline Update at a Glance

Investigators
Includes more than 121 principal companies plus their collaborators. There is direct access from inside the application to web pages of all principal companies.

Note: READ MORE >

Note: Product cover images may vary from those shown
2 of 2



Delivery Format: Desktop App plus Online Access to Updates (One Year)

Note: Product cover images may vary from those shown
3 of 2
Note: Product cover images may vary from those shown

RELATED PRODUCTS from Db